NCT03743883

EffectiveNess of Low-dose Aspirin in Prevention of Cancer in the Stomach and Oesophagus (GastrointEstinal Cancer Prevention) - United Kingdom ("ENgAGE - UK"): Study to Evaluate the Risk of Cancer in the Stomach and Oesophagus Among New Users of Low-dose Aspirin Using the THIN Database in the UK

Effectiveness of Low-dose Aspirin in Gastrointestinal Cancer Prevention -United Kingdom ("ENgAGE - UK"): A Cohort Study on the Risk of Gastric and Oesophageal Cancer Among New Users of Low-dose Aspirin Using the THIN Database in the UK

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 99,999 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 40 Years – 89 Years
• Healthy volunteers: Not accepted

Summary

Researchers already did studies in low-dose Aspirin for the prevention of heart and blood vessels disease and for the prevention of cancer of the colorectum. In this study, they want to learn whether an effect for the prevention of oesophagus cancer and stomach cancer goes along with the use of low-dose ASA on patients taking this medicine for the prevention of heart and blood vessels disease compared to non-use. To find this out electronic medical records stored in primary care database in the UK, The Health Improvement Network (THIN), will be used.

Conditions

• Prevention of Oesophagus Cancer and Stomach Cancer

Interventions

Type	Name	Description
DRUG	Acetylsalicylic Acid(BAYE4465, Aspirin )	Administration according to clinical practice

Timeline

• Start date: 2018-10-30
• Primary completion: 2019-04-15
• Completion: 2019-05-31
• First posted: 2018-11-16
• Last updated: 2020-06-01

Locations

1 site across 1 country: United Kingdom